-
Mashup Score: 32DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer - 17 hour(s) ago
Despite significant improvements in overall survival with PD-(L)1 inhibition, most patients with metastatic non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibition (ICI). Growing evidence suggests the importance of genomic alterations in modulating anti-cancer immune response and predicting ICI efficacy. However, the genomic correlates of response to ICI in NSCLC are largely unknown.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet
-
Mashup Score: 7
With widening therapeutic indications, germline genetic testing is offered to an increasing proportion of patients with breast cancer (BC) via mainstream oncology services. However, the gene set tested varies widely from just BRCA1/BRCA2 through to ‘pan-cancer’ panels of nearly 100 genes. If a germline pathogenic variant (GPV) is detected, the BC proband and other family GPV-carriers may be offered interventions such as risk-reducing surgery and intensive surveillance over decades for the various cancers linked to that gene.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
🆕 article in press: Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations https://t.co/bDzQ7i1rI3 https://t.co/ASVZqEC2a3
-
-
Mashup Score: 26
Despite the intracranial efficacy of osimertinib, CNS metastases remain a major cause of morbidity and mortality in EGFR-mutant non-small cell lung cancer (NSCLC). The genomic drivers of CNS dissemination are poorly understood.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
🆕 article in press: Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases https://t.co/G09MmduSWa https://t.co/XrKeW8aNBO
-
-
Mashup Score: 7
With widening therapeutic indications, germline genetic testing is offered to an increasing proportion of patients with breast cancer (BC) via mainstream oncology services. However, the gene set tested varies widely from just BRCA1/BRCA2 through to ‘pan-cancer’ panels of nearly 100 genes. If a germline pathogenic variant (GPV) is detected, the BC proband and other family GPV-carriers may be offered interventions such as risk-reducing surgery and intensive surveillance over decades for the various cancers linked to that gene.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
🆕 article in press: Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations https://t.co/bDzQ7i1rI3 https://t.co/ASVZqEC2a3
-
-
Mashup Score: 10
In this Article of the Month podcast Annals of Oncology Editor-in-Chief Tom Powles discusses the recently published study on WGS-powered ctDNA sequencing for breast cancer detection, with Prof. Nick
Source: soundcloud.comCategories: General Medicine NewsTweet-
🆕Article of the Month podcast🎧Prof. Nick Turner @ICR_London discusses whole genome sequencing-powered ctDNA sequencing for breast cancer detection with Annals of Oncology Editor-in-Chief @tompowles1 https://t.co/k62RDOEcmO To read the article see: https://t.co/87q8W2vwOm
-
-
Mashup Score: 40
Alterations in BRCA1/2 (BRCA) and other homologous recombination repair (HRR) genes have a negative impact on outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Poly(adenosine diphosphate-ribose) polymerase inhibitors, the only treatment demonstrated to improve the prognosis of patients with mCRPC, are also being developed for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). To fully assess their potential benefit in this setting, it is essential to understand how BRCA and HRR defects may influence the prognosis of conventionally treated patients with low- and high-disease volume.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
📢#ASCO25 concomitant publication: BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic HSPC: prevalence and impact on outcomes @Dolmos77 @Dav_Lorente @igginel @nromerolaorden @casilda_llacer @cdanicas @BerUrologia https://t.co/0qc58N0MhV https://t.co/vefiOWq8lA
-
-
Mashup Score: 18
After chemoradiotherapy (CRT), 30%-50% of patients with locally advanced cervical cancer (LACC) relapse, highlighting the unmet need for prognostic biomarkers. In the global randomized CALLA trial (NCT03830866), the addition of durvalumab during and after CRT did not significantly improve progression-free survival (PFS) in a biomarker-unselected intent-to-treat population. We analyzed the association of ultrasensitive circulating tumor DNA (ctDNA) and circulating human papilloma virus (cHPV) DNA detection with relapse and survival in the largest dataset in LACC to date.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet-
📢#ASCO25 concomitant publication: Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses https://t.co/vlBb1GaUoM https://t.co/pT9P6gZ6LR
-
-
Mashup Score: 10Dostarlimab and niraparib in primary advanced ovarian cancer - 17 day(s) ago
The combination of immunotherapies and poly (ADP-ribose) polymerase inhibitors (PARPis) has been hypothesized to improve outcomes in advanced ovarian cancer (aOC). The FIRST/ENGOT-OV44 trial evaluated adding dostarlimab to first-line platinum-based chemotherapy (PBCT) and niraparib maintenance ± bevacizumab in patients with aOC.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
📢#ASCO25 concomitant publication: Dostarlimab and niraparib in primary advanced ovarian cancer https://t.co/juE9qRwjXq https://t.co/ImoRrrgiEU
-
-
Mashup Score: 32
At the primary analysis of the EV-302 trial, enfortumab vedotin plus pembrolizumab (EV+P) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
📢#ASCO25 concomitant publication: Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-Year median follow-up of the phase III EV-302/KEYNOTE- A39 trial @tompowles1 https://t.co/X75FJ3r6Dz https://t.co/MIamBRjYPK
-
-
Mashup Score: 23Enzalutamide plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: results of the EORTC 1333/PEACE-3 trial. - 20 day(s) ago
PEACE-3 demonstrates that combining enzalutamide with Ra223 as first-line therapy for mCRPC significantly improves rPFS. Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet-
🆕article in press: Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial @BertrandTOMBAL, @Silke_Gillessen, @EORTC https://t.co/PT14VH8pcE https://t.co/IqDSHXc171
-
🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer https://t.co/ugmKnkLYZM @DrMarkAwad @BRicciutiMD https://t.co/naCqpPF2e8